Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
44
Recruiting, any sponsor type, condition "respiratory syncytial virus"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed267
44 trials
Showing 1 to 25, recently updated first.
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DosePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06866405 · 550 participants (planned) · Start Apr 16, 2025 · Primary completion Feb 24, 2028
Drug: RSVpreF; Placebo · For: RSV Infection
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 99 sites in all
- A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07768345 · 440 participants (planned) · Start Aug 31, 2026 · Primary completion Feb 2, 2028
Drug: RSVpreF Vaccine · For: Respiratory Syncytial Virus (RSV)
Sites: Los Angeles, California; Aurora, Colorado; Washington D.C., District of Columbia · 21 sites in all
- Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant RecipientsRecruiting
Seoul National University HospitalAcademic, hospital or other
NCT07895394 · 80 participants (planned) · Start Oct 27, 2026 · Primary completion Oct 2027
Drug: RSVPreF3 vaccination · For: Vaccination; Respiratory Syncytial Virus (RSV); Lung Transplant Recipient
Sites: Seoul, South Korea
SanofiSanofi (SNY)
NCT07200206 · 3,000 participants (planned) · Start Oct 2, 2025 · Primary completion Sep 26, 2029
Drug: Nirsevimab · For: Respiratory Syncytial Virus
Sites: Hwaseong-si, Gyeonggi-do, South Korea
- Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV DiseasePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07839871 · 920 participants (planned) · Start Sep 22, 2026 · Primary completion Mar 30, 2031
Drug: RSVpreF; Placebo · For: Respiratory Syncytial Virus (RSV)
Sites: Durham, North Carolina; Cincinnati, Ohio; South Euclid, Ohio · 20 sites in all
- Immunogenicity of RSVPreF3 Vaccine in Immunocompromised PersonsPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT07050732 · 170 participants (planned) · Start Dec 4, 2025 · Primary completion Apr 2027
Drug: Arexvy (2 doses total); Arexvy (3 doses total) and 1 more · For: Respiratory Syncytial Virus (RSV)
Sites: Baltimore, Maryland
- TARSILA Real-World Evidence StudyRecruiting
Inova MedicalAcademic, hospital or other
NCT07445763 · 5,000 participants (planned) · Start Apr 27, 2026 · Primary completion Sep 30, 2028
Drug: respiratory syncytial virus bivalent prefusion F vaccine · For: Respiratory Syncytial Virus (RSV); Maternal Immunization; Acute Respiratory Illness (ARI) and 2 more
Sites: Cascavel, Brazil; Curitiba, Brazil; Marechal Cândido Rondon, Brazil · 8 sites in all
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseasePivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07908381 · 860 participants (planned) · Start Oct 19, 2026 · Primary completion Jul 2029
Drug: zelicapavir; Placebo · For: RSV
Sites: Cape Coral, Florida; Miami, Florida; Bluffton, South Carolina · 4 sites in all
Yale UniversityAcademic, hospital or other
NCT06172660 · 3,750 participants (planned) · Start Oct 28, 2024 · Primary completion Dec 30, 2028
Drug: Nirsevimab · For: RSV Infection
Sites: New Haven, Connecticut
- A Study of BLB-201 RSV Vaccine in Infants and ChildrenPivotal-lookingRecruiting
Blue Lake Biotechnology Inc.Industry
NCT05655182 · 137 participants (planned) · Start Mar 9, 2023 · Primary completion Dec 30, 2028
Drug: PIV5-vectored RSV Vaccine (BLB-201) Low Dose; PIV5-vectored RSV Vaccine (BLB-201) High Dose and 1 more · For: Respiratory Syncytial Virus Infections
Sites: La Mesa, California; Modesto, California; San Diego, California · 18 sites in all
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseasePivotal-lookingRecruiting
ShionogiIndustry
NCT07214571 · 192 participants (planned) · Start Dec 11, 2025 · Primary completion Dec 30, 2026
Drug: S-337395; Placebo · For: Respiratory Syncytial Virus Infections
Sites: Los Angeles, California; Modesto, California; Toluca Lake, California · 89 sites in all
- Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07810010 · 8,000 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 3, 2028
Drug: Bivalent RSV+HMPV protein vaccine; Placebo · For: Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers
Sites: Bruse, Australia; Blacktown, Australia; Maroubra, Australia · 21 sites in all
- Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07734649 · 2,400 participants (planned) · Start Jul 22, 2026 · Primary completion May 3, 2028
Drug: RSV+HMPV vaccine; Control Vaccine 3 and 3 more · For: Respiratory Syncytial Virus Immunization; Human Metapneumovirus Immunization; Healthy Volunteers
Sites: Gadsden, Alabama; Vestavia Hills, Alabama; Huntington Beach, California · 50 sites in all
- A Study to Learn About the Safety and Immune Responses of RSVpreF in Older AdultsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07819097 · 600 participants (planned) · Start Sep 9, 2026 · Primary completion May 16, 2027
Drug: RSVpreF · For: Adult; Healthy Participants
Sites: Scottsdale, Arizona; Lake Forest, California; Riverside, California · 15 sites in all
- THRIVE - Trial of Passive Humoral RSV Immunity for Value and EffectivenessPivotal-lookingRecruiting
Menzies School of Health ResearchAcademic, hospital or other
NCT07578298 · 1,000 participants (planned) · Start Jun 17, 2026 · Primary completion Jul 31, 2030
Drug: Nirsevimab (RSV-specific monoclonal antibody) · For: Respiratory Syncytial Virus (RSV); Respiratory Infection Virus
Sites: Darwin, Australia
- Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)Pivotal-lookingRecruiting
Beijing BeneWill Technology Development Co., LtdAcademic, hospital or other
NCT07860216 · 25,000 participants (planned) · Start Aug 21, 2026 · Primary completion Dec 31, 2028
Drug: Recombinant respiratory syncytial virus vaccine (CHO cell); Sodium Chloride Injection 0.9% · For: Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)
Sites: GuiZhou, China; Hebei, China; HuBei, China · 7 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06817889 · 60 participants (planned) · Start Dec 23, 2025 · Primary completion Nov 30, 2027
Drug: Remdesivir · For: Hematopoietic and Lymphatic System Neoplasm; Autoimmune Disease; Respiratory Syncytial Virus Infection
Sites: Duarte, California; Houston, Texas; Seattle, Washington
- A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older AdultsPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07628049 · 1,456 participants (planned) · Start Jun 5, 2026 · Primary completion Apr 5, 2029
Drug: RSV/hMPV_V low dose vaccine; RSV/hMPV_V medium dose vaccine and 14 more · For: Respiratory Syncytial Virus Infections+Metapneumovirus
Sites: Stockbridge, Georgia; Lenexa, Kansas; Seattle, Washington · 5 sites in all
- A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07653100 · 540 participants (planned) · Start Jun 22, 2026 · Primary completion Jan 25, 2027
Drug: RSVpreF; Placebo · For: Respiratory Syncytial Virus (RSV)
Sites: Visakhapatnam, India; Bangalore, India; Belagavi, India · 13 sites in all
- rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderPivotal-lookingRecruiting
Biothervax SpAIndustry
NCT07762014 · 200 participants (planned) · Start Sep 14, 2026 · Primary completion Sep 7, 2027
Drug: Vaccination with rBCG-N-RSV; Vaccination with conventional BCG (BCG-WT) · For: Respiratory Syncytial Virus Infection Prevention; Tuberculosis Prevention
Sites: Athens, Greece
- A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 InjectionPivotal-lookingRecruiting
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.Industry
NCT07694557 · 180 participants (planned) · Start Jul 29, 2026 · Primary completion Jul 1, 2028
Drug: YKYY025 group; YKYY025 Placebo group · For: Respiratory Syncytial Virus (RSV)
Sites: Anning, China
- A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsPivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07764237 · 375 participants (planned) · Start Aug 11, 2026 · Primary completion Jul 20, 2027
Drug: mRNA-1365 (Profile 2); mRNA-1345 (Profile 1) and 1 more · For: Respiratory Syncytial Virus (RSV); Human Metapneuomovirus (hMPV)
Sites: Québec, Canada; Victoriaville, Canada; Manchester, United Kingdom · 10 sites in all
- PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)Pivotal-lookingRecruiting
Pulmotect, Inc.Industry
NCT06665100 · 100 participants (planned) · Start Jun 27, 2025 · Primary completion Apr 2027
Drug: PUL-042; Placebo · For: Hematologic Malignancies; Hematopoietic Stem Cell Transplant (HSCT)
Sites: Duarte, California; Atlanta, Georgia; Baltimore, Maryland · 12 sites in all
SynAct Pharma ApsIndustry
NCT07633288 · 96 participants (planned) · Start May 1, 2026 · Primary completion Aug 1, 2027
Drug: AP1189, 100 mg; Placebo · For: Respiratory Viral Infection
Sites: Mostar, Bosnia and Herzegovina; Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina · 11 sites in all
- A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusPivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07482657 · 150 participants (planned) · Start Jul 9, 2026 · Primary completion Dec 2026
Drug: zelicapavir; Placebo · For: RSV Infection; RSV; Respiratory Syncytial Virus (RSV)
Sites: Bangkok, Thailand; Chiang Mai, Thailand; Chiang Rai, Thailand · 8 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.